---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-072805"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2025-08-01T23:59:59+00:00"
generated_at: "2026-05-17T21:45:04.772653+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# CytoSorbents highlights new sepsis studies showing improved survival with early, intensive CytoSorb use

## Summary
- Meta-analysis of 744 septic shock patients: CytoSorb reduced in-hospital mortality (OR 0.64, p=0.036) and halved 28–30 day mortality (OR 0.46, p=0.003).
- Berlot et al. study of 175 patients: early intensive CytoSorb use (≥3 cartridges in 2–3 days) nearly doubled survival (70% observed vs 37% predicted).
- 100-patient U.S. COVID-19 registry on ECMO: 74% 90-day survival, rising to 82% with early treatment, outperforming ~50% benchmarks.
- Company to host World Sepsis Day Global Webinar on September 10, 2025 to discuss CytoSorb best practices.

## SEC filing metadata
- accession: 0001104659-25-072805
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2025-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465925072805/0001104659-25-072805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465925072805/tm2522255d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-072805
- JSON: https://secwatch.observer/filing/0001104659-25-072805.json
- Plain text: https://secwatch.observer/filing/0001104659-25-072805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.